Company Description
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Timothy Dyer |
Contact Details
Address: Chemin des Mines, 9 Geneva, 1202 Switzerland | |
| Phone | 41 22 884 1555 |
| Website | addextherapeutics.com |
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J107 |
| ISIN Number | US00654J2069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer and Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer and Director |
| Lénaic Teyssédou | Head of Finance |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 19, 2024 | 6-K | Report of foreign issuer |
| Aug 27, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 22, 2024 | 6-K | Report of foreign issuer |
| Jul 15, 2024 | 6-K | Report of foreign issuer |
| Jul 1, 2024 | 6-K | Report of foreign issuer |